

## 510(k) Summary

100274

Date Prepared:

January 28, 2010

MAY 1 0 2010

Submitter:

Medtronic

7611 Northland Drive Minneapolis, MN 55428

Establish Registration Number: 2184009

Contact Person:

Caralee Walton

Senior Regulatory Affairs Specialist

Phone: (763) 514-9851 Fax: (763) 367-8360

Email: caralee.a.walton@medtronic.com

#### **Device Name and Classification**

Trade Name:

MiAR<sup>TM</sup> (Minimally Invasive) Aortic Root Cannula with Flow-

Guard<sup>TM</sup>

Common Name:

Cardiopulmonary bypass vascular catheter, cannula, or tubing

Regulation Number: 21 CFR 870.4210

Product Code:

**DWF** Class II

Classification:

### **Predicate Devices**

Medtronic DLP Aortic Root Cannula (K790565) Medtronic Pediatric Aortic Root Cannula (K040173)

#### **Device Description**

MiAR<sup>TM</sup> Cannulae are single-use, sterile, nonpyrogenic devices designed to deliver cardioplegia through the aorta in an antegrade manner, for periods up to six hours during cardiopulmonary bypass surgery. These devices are available in models that feature two tip sizes and the Flow-Guard<sup>TM</sup> feature to maintain hemostasis during removal of the introducer needle from the cannula. The increased overall length of these cannulae relative to standard models, make them easier to use when minimally invasive surgical approaches are utilized (i.e., mini-sternotomy and right thoracotomy).

#### Indications for Use

The MiAR<sup>TM</sup> cannula is intended for use during cardiopulmonary bypass for the delivery of cardioplegia for up to 6 hours. The cannula may also be used to aspirate air from the aorta at the conclusion of the bypass procedure. It is indicated for use during cardiac surgery for median sternotomy or minimally invasive (mini-sternotomy or right thoracotomy) access using direct visualization techniques.

#### **Comparison to Predicate Devices**

A comparison of the modified product and the currently marketed Aortic Root Cannula indicates the following similarities to the device which received 510(k) clearance:

- Same technological characteristics
- Same operating principle
- Same design features, only longer length
- Same Flow-Guard™ introducer
- Same connectors
- Same materials
- Same shelf life

#### **Summary of Performance Data**

Bench testing was used to establish the performance characteristics of the modifications of this device from previously marketed Medtronic cannula devices. Clinical testing was not required to establish substantial equivalence. The following performance tests were conducted:

- Flow Rate Versus Pressure Drop
- Distal tip visibility Under Fluoroscopic Visualization
- Structural Integrity (bonded joints)

#### Conclusion

Medtronic has demonstrated that the MiAR<sup>TM</sup> Cannulae are substantially equivalent to the predicate device based upon design and test results. Any noted differences do not raise new issues of safety and effectiveness.



Food and Drug Administration 10903 New Hampshire Avenue Document Control Room W-O66-0609 Silver Spring, MD 20993-0002

MAY 1 0 2010

Medtronic, Inc. c/o Ms. Caralee A. Walton Senior Regulatory Affairs Specialist 710 Medtronic Parkway NE Minneapolis, MN 55432

Re: K100274

MiAR<sup>TM</sup> (Minimally Invasive) Aortic Root Cannula with Flow-Guard<sup>TM</sup>

Regulation Number: 21 CFR 870.4210

Regulation Name: Cardiopulmonary bypass vascular catheter, cannula, or tubing

Regulatory Class: II Product Code: DWF Dated: May 3, 2010 Received: May 4, 2010

Dear Ms. Walton:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act

or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to <a href="http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm">http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm</a> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Bram D. Zuckerman, M.D.

Director

Division of Cardiovascular Devices

onna & hichan

Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure

# **Indications for Use**

510(k) Number (if known): <u>K100274</u>
Device Name: MiAR™ Aortic Root Cannula with Flow-Guard™
Indications for Use:
The MiAR™ cannula is intended for use during cardiopulmonary bypass for the delivery of cardioplegia up to 6 hours. The cannula may also be used to aspirate air from the aorta at the conclusion of the bypass procedure. It is indicated for use during cardiac surgery for median sternotomy or minimally invasive (mini-sternotomy or right thoracotomy) access using direct visualization techniques.
Prescription Use X Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
(Division Sign-Off) Division of Cardiovascular Devices
510(k) Number <u>K\0 0274</u>